MCL1 and T-cell non-Hodgkin lymphoma: Similarly, S63845, a selective MCL-1 inhibitor, demonstrates potent anti-leukemic activity across diverse hematological malignancies, including T-cell lymphomas, where MCL-1–mediated resistance often limits the efficacy of BCL-2 antagonists [64].